-
Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion Cell. Oncol. (IF 6.6) Pub Date : 2024-04-25 Yangzi Li, Qingya Cui, Sining Liu, Lingling Liu, Megyn Li, Jun Gao, Zheng Li, Wei Cui, Xiaming Zhu, Liqing Kang, Lei Yu, Depei Wu, Xiaowen Tang
-
LILRB2 promotes immune escape in breast cancer cells via enhanced HLA-A degradation Cell. Oncol. (IF 6.6) Pub Date : 2024-04-24 Zhiyuan Jiang, Qianru Huang, Yujie Chang, Yiran Qiu, Hao Cheng, Mengdi Yang, Shunyi Ruan, Suyuan Ji, Jing Sun, Zhiyu Wang, Shengyuan Xu, Rui Liang, Xueyu Dai, Kejin Wu, Bin Li, Dan Li, Hui Zhao
-
Chordoma cells possess bone-dissolving activity at the bone invasion front Cell. Oncol. (IF 6.6) Pub Date : 2024-04-23 Katsuhiro Kawaai, Yumiko Oishi, Yukiko Kuroda, Ryota Tamura, Masahiro Toda, Koichi Matsuo
-
Exploring the impact of PDGFD in osteosarcoma metastasis through single-cell sequencing analysis Cell. Oncol. (IF 6.6) Pub Date : 2024-04-23 Yujing Huang, Dongyan Cao, Manxue Zhang, Yue Yang, Gengming Niu, Lina Tang, Zan Shen, Zhichang Zhang, Yueqing Bai, Daliu Min, Aina He
-
Correction to: Microbial metabolite trimethylamine-N-oxide induces intestinal carcinogenesis through inhibiting farnesoid X receptor signaling Cell. Oncol. (IF 6.6) Pub Date : 2024-04-16 Wanru Zhang, Xiali Qin, Kexin Zhang, Jiahui Ma, Mengfan Li, Ge Jin, Xiang Liu, Sinan Wang, Bangmao Wang, Jing Wu, Tianyu Liu, Weilong Zhong, Hailong Cao
-
Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals immune suppression subtypes and establishes a novel signature for determining the prognosis in lung adenocarcinoma Cell. Oncol. (IF 6.6) Pub Date : 2024-04-15 Shengqiang Mao, Yilong Wang, Ningning Chao, Lingyan Zeng, Li Zhang
-
The emerging role of CARM1 in cancer Cell. Oncol. (IF 6.6) Pub Date : 2024-04-15 Zizhuo Xie, Yuan Tian, Xiaohan Guo, Na Xie
-
Establishment, characterization, and biobanking of 36 pancreatic cancer organoids: prediction of metastasis in resectable pancreatic cancer Cell. Oncol. (IF 6.6) Pub Date : 2024-04-15 Soon-Chan Kim, Ha-Young Seo, Ja-Oh Lee, Ju Eun Maeng, Young-Kyoung Shin, Sang Hyub Lee, Jin-Young Jang, Ja-Lok Ku
-
Downregulation of GPX8 in hepatocellular carcinoma: impact on tumor stemness and migration Cell. Oncol. (IF 6.6) Pub Date : 2024-04-12 Chen-Yang Tao, Xiao-Ling Wu, Shu-Shu Song, Zheng Tang, Yu-Fu Zhou, Meng-Xin Tian, Xi-Fei Jiang, Yuan Fang, Gui-Qi Zhu, Run Huang, Wei-Feng Qu, Jun Gao, Tian-Hao Chu, Rui Yang, Jia-Feng Chen, Qian-Fu Zhao, Zhen-Bin Ding, Zhi Dai, Jian Zhou, Wei-Ren Liu, Ying-Hong Shi, Jia Fan
-
Dexmedetomidine promotes colorectal cancer progression via Piwil2 signaling Cell. Oncol. (IF 6.6) Pub Date : 2024-04-09 Jing Dong, Ji Che, Yuanyuan Wu, Yixu Deng, Xuliang Jiang, Zhiyong He, Jun Zhang
-
Hedgehog ligand and receptor cooperatively regulate EGFR stability and activity in non-small cell lung cancer Cell. Oncol. (IF 6.6) Pub Date : 2024-04-03 Aidi Huang, Junyao Cheng, Yuan Zhan, Feifei Zhou, Yanlu Xuan, Yiting Wang, Qingjie Chen, Hailong Wang, Xinping Xu, Shiwen Luo, Minzhang Cheng
Purpose The hyperactivation of epidermal growth factor receptor (EGFR) plays a crucial role in non-small cell lung cancer (NSCLC). Hedgehog (Hh) signaling has been implicated in the tumorigenesis and progression of various cancers, however, its function in NSCLC cells remains controversial. Herein, we present a novel finding that challenges the current understanding of Hh signaling in tumor growth
-
Copy number signatures and CCNE1 amplification reveal the involvement of replication stress in high-grade endometrial tumors oncogenesis Cell. Oncol. (IF 6.6) Pub Date : 2024-04-02 Regine Marlin, Jean-Samuel Loger, Clarisse Joachim, Coralie Ebring, Guillaume Robert-Siegwald, Sabrina Pennont, Mickaelle Rose, Kevin Raguette, Valerie Suez-Panama, Sylviane Ulric-Gervaise, Sylvie Lusbec, Odile Bera, Alexis Vallard, Aude Aline-Fardin, Emeline Colomba, Mehdi Jean-Laurent
Purpose Managing high-grade endometrial cancer in Martinique poses significant challenges. The diversity of copy number alterations in high-grade endometrial tumors, often associated with a TP53 mutation, is a key factor complicating treatment. Due to the high incidence of high-grade tumors with poor prognosis, our study aimed to characterize the molecular signature of these tumors within a cohort
-
Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma Cell. Oncol. (IF 6.6) Pub Date : 2024-04-02 Xiangke Xin, Xiaojian Zhu, Yang Yang, Na Wang, Jue Wang, Jinhuan Xu, Jia Wei, Liang Huang, Miao Zheng, Yi Xiao, Chunrui Li, Yang Cao, Fankai Meng, Lijun Jiang, Yicheng Zhang
Introduction Chimeric antigen receptor (CAR)-T cells obtained long-term durability in about 30% to 40% of relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). Maintenance therapy after CAR-T is necessary, and PD1 inhibitor is one of the important maintenance therapy options. Methods A total of 173 r/r B-NHL patients treated with PD1 inhibitor maintenance following CD19/22 CAR-T therapy alone
-
IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling Cell. Oncol. (IF 6.6) Pub Date : 2024-03-27 Tian-Hao Li, Bang-Bo Zhao, Cheng Qin, Yuan-Yang Wang, Ze-Ru Li, Hong-Tao Cao, Xiao-Ying Yang, Xing-Tong Zhou, Wei-Bin Wang
-
3D bioprinted tumor model: a prompt and convenient platform for overcoming immunotherapy resistance by recapitulating the tumor microenvironment Cell. Oncol. (IF 6.6) Pub Date : 2024-03-23 Zhangyi Zhang, Xuebo Chen, Sujie Gao, Xuedong Fang, Shengnan Ren
-
DNA hypomethylation patterns and their impact on the tumor microenvironment in colorectal cancer Cell. Oncol. (IF 6.6) Pub Date : 2024-03-23
Abstract Background Recent research underscores the pivotal role of immune checkpoints as biomarkers in colorectal cancer (CRC) therapy, highlighting the dynamics of resistance and response to immune checkpoint inhibitors. The impact of epigenetic alterations in CRC, particularly in relation to immune therapy resistance, is not fully understood. Methods We integrated a comprehensive dataset encompassing
-
Multi-dimensional characterization of apoptosis in the tumor microenvironment and therapeutic relevance in melanoma Cell. Oncol. (IF 6.6) Pub Date : 2024-03-19 Jing Ye, Benliang Wei, Guowei Zhou, Yantao Xu, Yi He, Xiheng Hu, Xiang Chen, Guanxiong Zhang, Hong Liu
-
The Ribonuclease ZC3H12A is required for self-inflicted DNA breaks after DNA damage in small cell lung cancer cells Cell. Oncol. (IF 6.6) Pub Date : 2024-03-18 Mingjun Lu, Qing Gao, Renjing Jin, Meng Gu, Ziyu Wang, Xiaobo Li, Weiying Li, Jinghui Wang, Teng Ma
-
Mapping the immune terrain in lung adenocarcinoma progression: Tfh-like cells in tertiary lymphoid structures Cell. Oncol. (IF 6.6) Pub Date : 2024-03-16 Jialei Gong, Di Yu
-
Identification of a novel gene signature related to prognosis and metastasis in gastric cancer Cell. Oncol. (IF 6.6) Pub Date : 2024-03-13 Joseba Elizazu, Aizpea Artetxe-Zurutuza, Maddalen Otaegi-Ugartemendia, Veronica Moncho-Amor, Manuel Moreno-Valladares, Ander Matheu, Estefania Carrasco-Garcia
-
CAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistance Cell. Oncol. (IF 6.6) Pub Date : 2024-03-07 Diane Coursier, Fernando Calvo
-
STK3 kinase activation inhibits tumor proliferation through FOXO1-TP53INP1/P21 pathway in esophageal squamous cell carcinoma Cell. Oncol. (IF 6.6) Pub Date : 2024-03-04
Abstract Purpose Esophageal squamous cell carcinoma (ESCC) is an aggressive disease with a poor prognosis, caused by the inactivation of critical cell growth regulators that lead to uncontrolled proliferation and increased malignancy. Although Serine/Threonine Kinase 3 (STK3), also known as Mammalian STE20-like protein kinase 2 (MST2), is a highly conserved kinase of the Hippo pathway, plays a critical
-
The predictive significance of chromobox family members in prostate cancer in humans Cell. Oncol. (IF 6.6) Pub Date : 2024-03-01 Xiaoting Xu, Cong Lai, Jiawen Luo, Juanyi Shi, Kaixuan Guo, Jintao Hu, Yelisudan Mulati, Yunfei Xiao, Degeng Kong, Cheng Liu, Jingang Huang, Kewei Xu
-
The prognostic effect of tumor-associated macrophages in stage I-III colorectal cancer depends on T cell infiltration Cell. Oncol. (IF 6.6) Pub Date : 2024-02-26 Umair Majid, Christian Holst Bergsland, Anita Sveen, Jarle Bruun, Ina Andrassy Eilertsen, Espen S. Bækkevold, Arild Nesbakken, Sheraz Yaqub, Frode L. Jahnsen, Ragnhild A. Lothe
-
Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma Cell. Oncol. (IF 6.6) Pub Date : 2024-02-23 Tingyu Liu, Xin Yue, Xue Chen, Ru Yan, Chong Wu, Yunzhi Li, Xianzhang Bu, Hui Han, Ran-Yi Liu
-
PIN1 promotes the metastasis of cholangiocarcinoma cells by RACK1-mediated phosphorylation of ANXA2 Cell. Oncol. (IF 6.6) Pub Date : 2024-02-22 Yuming Wang, Yiwei Liu, Hairong Chen, Zhenggang Xu, Wangjie Jiang, Xiao Xu, Jijun Shan, Jiang Chang, Tao Zhou, Jifei Wang, Anlan Chenyan, Shilong Fan, Zifan Tao, Ke Shao, Xiangcheng Li, Xiaofeng Chen, Guwei Ji, Xiaofeng Wu
-
GDF15 induces chemoresistance to oxaliplatin by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis in colorectal cancer Cell. Oncol. (IF 6.6) Pub Date : 2024-02-22 Haiping Lin, Yang Luo, Tingyue Gong, Hongsheng Fang, Hao Li, Guangyao Ye, Yan Zhang, Ming Zhong
-
O-GlcNAcylation of TRIM29 and OGT translation forms a feedback loop to promote adaptive response of PDAC cells to glucose deficiency Cell. Oncol. (IF 6.6) Pub Date : 2024-02-12
Abstract Purpose Glucose not only provides energy for tumor cells, but also provides various biomolecules that are essential for their survival, proliferation and invasion. Therefore, it is of great clinical significance to understand the mechanism of how tumor cells adapt to metabolic stress and maintain their survival. The aim of this research was to study the critical role of OGT and TRIM29 O-GlcNAc
-
Emerging roles of deubiquitinating enzymes in actin cytoskeleton and tumor metastasis Cell. Oncol. (IF 6.6) Pub Date : 2024-02-07
Abstract Background Metastasis accounts for the majority of cancer-related deaths. Actin dynamics and actin-based cell migration and invasion are important factors in cancer metastasis. Metastasis is characterized by actin polymerization and depolymerization, which are precisely regulated by molecular changes involving a plethora of actin regulators, including actin-binding proteins (ABPs) and signalling
-
Repaglinide restrains HCC development and progression by targeting FOXO3/lumican/p53 axis Cell. Oncol. (IF 6.6) Pub Date : 2024-02-07 Yifei Tan, Yongjie Zhou, Wei Zhang, Zhenru Wu, Qing Xu, Qiong Wu, Jian Yang, Tao Lv, Lvnan Yan, Hong Luo, Yujun Shi, Jiayin Yang
-
Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy Cell. Oncol. (IF 6.6) Pub Date : 2024-02-06 Shuaibo Wang, Xujie Sun, Jiyan Dong, Li Liu, Hao Zhao, Renda Li, Zhenlin Yang, Na Cheng, Yalong Wang, Li Fu, Hang Yi, Zhuoheng Lv, Huandong Huo, Donghui Jin, Yousheng Mao, Lin Yang
-
Targeting MEK/COX-2 axis improve immunotherapy efficacy in dMMR colorectal cancer with PIK3CA overexpression Cell. Oncol. (IF 6.6) Pub Date : 2024-02-05
Abstract Purpose PIK3CA mutation or overexpression is associated with immunotherapy resistance in multiple cancer types, but is also paradoxically associated with benefit of COX-2 inhibition on patient survival of colorectal cancer (CRC) with mismatch repair deficiency (dMMR). This study examined whether and how PIK3CA status affected COX-2-mediated tumor inflammation and immunotherapy response of
-
OTUB1 accelerates hepatocellular carcinoma by stabilizing RACK1 via its non-canonical ubiquitination Cell. Oncol. (IF 6.6) Pub Date : 2024-02-05 Liqun Peng, Tiangen Wu, Yingyi Liu, Dongli Zhao, Wenzhi He, Yufeng Yuan
-
A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma Cell. Oncol. (IF 6.6) Pub Date : 2024-02-05
Abstract Purpose Although mRNA vaccines have shown certain clinical benefits in multiple malignancies, their therapeutic efficacies against hepatocellular carcinoma (HCC) remains uncertain. This study focused on establishing a novel risk score system based on immune subtypes so as to identify optimal HCC mRNA vaccination population. Methods GEPIA, cBioPortal and TIMER databases were utilized to identify
-
DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma Cell. Oncol. (IF 6.6) Pub Date : 2024-02-05 Rui Li, Xin Wen, Ru-xue Lv, Xian-yue Ren, Bing-lin Cheng, Yi-kai Wang, Ru-zhen Chen, Wen Hu, Xin-Ran Tang
-
Microbial metabolite trimethylamine-N-oxide induces intestinal carcinogenesis through inhibiting farnesoid X receptor signaling Cell. Oncol. (IF 6.6) Pub Date : 2024-02-05
Abstract Purpose Microbial dysbiosis is considered as a hallmark of colorectal cancer (CRC). Trimethylamine-N-oxide (TMAO) as a gut microbiota-dependent metabolite has recently been implicated in CRC development. Nevertheless, evidence relating TMAO to intestinal carcinogenesis remains largely unexplored. Herein, we aimed to examine the crucial role of TMAO in CRC progression. Methods Apcmin/+ mice
-
Robust detection of clinically relevant features in single-cell RNA profiles of patient-matched fresh and formalin-fixed paraffin-embedded (FFPE) lung cancer tissue Cell. Oncol. (IF 6.6) Pub Date : 2024-02-01 Alexandra Trinks, Miha Milek, Dieter Beule, Julie Kluge, Stefan Florian, Christine Sers, David Horst, Markus Morkel, Philip Bischoff
-
Omics-based molecular classifications empowering in precision oncology Cell. Oncol. (IF 6.6) Pub Date : 2024-01-31
Abstract Background In the past decades, cancer enigmatical heterogeneity at distinct expression levels could interpret disparities in therapeutic response and prognosis. It built hindrances to precision medicine, a tactic to tailor customized treatment informed by the tumors’ molecular profile. Single-omics analysis dissected the biological features associated with carcinogenesis to some extent but
-
NK cells as powerful therapeutic tool in cancer immunotherapy Cell. Oncol. (IF 6.6) Pub Date : 2024-01-03 Mao Huang, Yixuan Liu, Qijia Yan, Miao Peng, Junshang Ge, Yongzhen Mo, Yumin Wang, Fuyan Wang, Zhaoyang Zeng, Yong Li, Chunmei Fan, Wei Xiong
-
Extracellular vesicles related gene HSPH1 exerts anti-tumor effects in prostate cancer via promoting the stress response of CD8 + T cells Cell. Oncol. (IF 6.6) Pub Date : 2024-01-02
Abstract Background T cell stress response state (TSTR), as a novel immune concept previous studies have proposed, has not yet been explored in prostate cancer (PC). As a type of cellular efflux, exosomes play important roles in the occurrence and development of PC. Method Here, we conducted a combined analysis on extracellular vesicle related genes (EVRGs) in PC using data from single-cell RNA (scRNA)
-
Asymmetric post-translational modifications regulate the nuclear translocation of STAT3 homodimers in response to leukemia inhibitory factor Cell. Oncol. (IF 6.6) Pub Date : 2023-12-27
Abstract STAT3 is a pleiotropic transcription factor overactivated in 70% of solid tumours. We have recently reported that inactivating mutations on residues susceptible to post-translational modifications (PTMs) in only one of the monomers (i.e. asymmetric) caused changes in the cellular distribution of STAT3 homodimers. Here, we used more controlled experimental conditions, i.e. without the interference
-
ITGB2-ICAM1 axis promotes liver metastasis in BAP1-mutated uveal melanoma with retained hypoxia and ECM signatures Cell. Oncol. (IF 6.6) Pub Date : 2023-12-27
Abstract Purpose Uveal melanoma (UM) with BAP1 inactivating mutations has a high risk of metastasis, but the mechanism behind BAP1 deficiency driving UM metastasis is unknown. Methods We analyzed the single-cell RNA sequencing (scRNA-Seq) data comprised primary and metastatic UM with or without BAP1 mutations (MUTs) to reveal inter- and intra-tumor heterogeneity among different groups. Then, an immune-competent
-
Sirtuin 5-mediated deacetylation of TAZ at K54 promotes melanoma development Cell. Oncol. (IF 6.6) Pub Date : 2023-12-19 Garam Kim, Poshan Yugal Bhattarai, Sung-Chul Lim, Kwang Youl Lee, Hong Seok Choi
-
ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma Cell. Oncol. (IF 6.6) Pub Date : 2023-12-15 Yang Liu, Yizhi Cao, Pengyi Liu, Shuyu Zhai, Yihao Liu, Xiaomei Tang, Jiayu Lin, Minmin Shi, Debin Qi, Xiaxing Deng, Youwei Zhu, Weishen Wang, Baiyong Shen
-
DNA repair in tumor radioresistance: insights from fruit flies genetics Cell. Oncol. (IF 6.6) Pub Date : 2023-12-14 Antonella Porrazzo, Matteo Cassandri, Andrea D’Alessandro, Patrizia Morciano, Rossella Rota, Francesco Marampon, Giovanni Cenci
-
CSGALNACT2 restricts ovarian cancer migration and invasion by modulating MAPK/ERK pathway through DUSP1 Cell. Oncol. (IF 6.6) Pub Date : 2023-12-12 Mingjun Ma, Chao Wang, Meixuan Wu, Sijia Gu, Jiani Yang, Yue Zhang, Shanshan Cheng, Shilin Xu, Minghai Zhang, Yongsong Wu, Yaqian Zhao, Xiu Tian, Dominic Chih-Cheng Voon, Chiaki Takahashi, Jindan Sheng, Yu Wang
-
SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma Cell. Oncol. (IF 6.6) Pub Date : 2023-12-06 Zengbin Wang, Banglun Pan, Lili Su, Huahui Yu, Xiaoxuan Wu, Yuxin Yao, Xiaoxia Zhang, Jiacheng Qiu, Nanhong Tang
-
The development of in vitro organotypic 3D vulvar models to study tumor-stroma interaction and drug efficacy Cell. Oncol. (IF 6.6) Pub Date : 2023-12-07 Shidi Wu, Bertine W. Huisman, Marion H. Rietveld, Robert Rissmann, Maarten H. Vermeer, Mariette I. E. van Poelgeest, Abdoelwaheb El Ghalbzouri
-
HPV16 E6/E7-mediated regulation of PiwiL1 expression induces tumorigenesis in cervical cancer cells Cell. Oncol. (IF 6.6) Pub Date : 2023-12-01 Midhunaraj Kunnummal, Pooja Sherly Raveendran, Budhaditya Basu, Sheri Vidya Rani, Riya Ann Paul, Krithiga Kuppusamy, Mary Angelin, Joby Issac, Jackson James, Ani V. Das
-
Stiffened tumor microenvironment enhances perineural invasion in breast cancer via integrin signaling Cell. Oncol. (IF 6.6) Pub Date : 2023-11-28 Bing Han, Xin Guan, Mingyue Ma, Baoling Liang, Linglie Ren, Yutong Liu, Ye Du, Shu-Heng Jiang, Dong Song
-
CHIP promotes CAD ubiquitination and degradation to suppress the proliferation and colony formation of glioblastoma cells Cell. Oncol. (IF 6.6) Pub Date : 2023-11-20 Guanya Li, Kai Xiao, Yinan Li, Jianfang Gao, Shanping He, Tingting Li
-
TIPRL1 and its ATM-dependent phosphorylation promote radiotherapy resistance in head and neck cancer Cell. Oncol. (IF 6.6) Pub Date : 2023-11-16 Célie Cokelaere, Rüveyda Dok, Emanuela E. Cortesi, Peihua Zhao, Anna Sablina, Sandra Nuyts, Rita Derua, Veerle Janssens
-
Silencing AHNAK promotes nasopharyngeal carcinoma progression by upregulating the ANXA2 protein Cell. Oncol. (IF 6.6) Pub Date : 2023-11-14 Xingxing Lu, Yan Mei, Chunmei Fan, Pan Chen, Xiayu Li, Zhaoyang Zeng, Guiyuan Li, Wei Xiong, Bo Xiang, Mei Yi
-
The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer Cell. Oncol. (IF 6.6) Pub Date : 2023-11-09 Cristina Di Giorgio, Rachele Bellini, Antonio Lupia, Carmen Massa, Ginevra Urbani, Martina Bordoni, Silvia Marchianò, Rosalinda Rosselli, Rosa De Gregorio, Pasquale Rapacciuolo, Valentina Sepe, Elva Morretta, Maria Chiara Monti, Federica Moraca, Luigi Cari, Khan Rana Sami Ullah, Nicola Natalizi, Luigina Graziosi, Eleonora Distrutti, Michele Biagioli, Bruno Catalanotti, Annibale Donini, Angela Zampella
-
Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomach Cell. Oncol. (IF 6.6) Pub Date : 2023-11-09 Jingtao Wei, Ke Ji, Yue Zhang, Ji Zhang, Xiaojiang Wu, Xin Ji, Kai Zhou, Xuesong Yang, Hongfeng Lu, Anqiang Wang, Zhaode Bu
-
Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer Cell. Oncol. (IF 6.6) Pub Date : 2023-11-07 Ellen Finnegan, Wei Ding, Ziga Ude, Sara Terer, Tadhg McGivern, Anna M. Blümel, Grainne Kirwan, Xinxin Shao, Flavia Genua, Xiaofei Yin, Alexander Kel, Sarinj Fattah, Parvathi A. Myer, Sally-Ann Cryan, Jochen H. M. Prehn, Darran P. O’Connor, Lorraine Brennan, Gregory Yochum, Celine J. Marmion, Sudipto Das
-
Cancer/testis-45A1 promotes cervical cancer cell tumorigenesis and drug resistance by activating oncogenic SRC and downstream signaling pathways Cell. Oncol. (IF 6.6) Pub Date : 2023-11-04 Mei Meng, Yan Guo, Yu Chen, Xu Li, Bin Zhang, Zhijia Xie, Juntao Liu, Zhe Zhao, Yuxi Liu, Tong Zhang, Yingnan Qiao, Bingxue Shang, Quansheng Zhou
-
TRPV1 inhibition suppresses non-small cell lung cancer progression by inhibiting tumour growth and enhancing the immune response Cell. Oncol. (IF 6.6) Pub Date : 2023-10-30 Yang Wang, Yu Zhang, Jing Ouyang, Hanying Yi, Shiyu Wang, Dongbo Liu, Yingying Dai, Kun Song, Wenwu Pei, Ziyang Hong, Ling Chen, Wei Zhang, Zhaoqian Liu, Howard L. Mcleod, Yijing He
-
E3 ligase SOCS3 regulates NOD2 expression by ubiquitin proteasome system in lung cancer progression Cell. Oncol. (IF 6.6) Pub Date : 2023-11-01 In-ho Jeong, Jae Kwang Yun, Jun-O Jin, Jeong Hee Hong, Ji Yeon Lee, Geun Dong Lee, Peter Chang-Whan Lee
-
Retraction Note: IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. Cell. Oncol. (IF 6.6) Pub Date : 2023-10-30 Tian-Hao Li,Bang-Bo Zhao,Cheng Qin,Yuan-Yang Wang,Ze-Ru Li,Hong-Tao Cao,Xiao-Ying Yang,Xing-Tong Zhou,Wei-Bin Wang